Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by FredTheVoiceon May 02, 2020 9:07am

207 Views

Post# 30979096

RE:New Corp presentation posted

Pretty good presentation, on all points, oncology is explained very well.....

Here are the conclusions:

2020 Key Goals and Milestones

Continued Growth in HIV

Expand market acceptance of Trogarzo® in the U.S.
Secure reimbursement and launch of Trogarzo® in the EU
Advance Phase 3 development of Trogarzo® IV Push
Secure reimbursement for EGRIFTA SVTM and switch patients over from previous formulationAdvance Novel Pipeline

Initiate confirmatory bioequivalence study of tesamorelin F8 formulation in Q2 2020
Initiate Phase 3 trial of tesamorelin for the treatment of HIV-associated NASH by end of 2020
Initiate Phase 1 development of SORT1+ technology in cancer in late 2020/early 2021 Maintain Financial Strength